KEQU: FY2026 revenue and EBITDA surged, driven by platform integration and global expansion
Menos de 1 minuto de lectura
Revenue and EBITDA saw significant growth over five years, with FY2026 revenue at $282M and EBITDA at $22.4M. Strategic initiatives included the formation of the Lab Products Group, international expansion, and enhanced governance. Key risks and forward-looking statements were discussed.
Original document: Kewaunee Scientific Corporation [KEQU] Slides Release — Aug. 26 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr